Mbx Biosciences, INC S-1 registration statements

MBX Biosciences, Inc. increased its public offering by 1,274,263 common stock shares, including over-allotment options, through a Rule 462(b) filing.

MBX Biosciences announced a public offering of 10 million common shares following positive topline Phase 2 clinical trial results for its lead candidate, canvuparatide, for chronic hypoparathyroidism.

MBX Biosciences has filed a registration statement to increase its common stock offering by 1,955,000 shares, including an underwriter option, representing no more than 20% of the initial offering price.

MBX Biosciences, a clinical-stage biopharmaceutical company, files an amendment to its S-1 registration statement for a proposed initial public offering of 8,500,000 shares of common stock, aiming to raise approximately $114.8 million for continued development of its precision peptide therapies.

MBX Biosciences advances its IPO plans with an amendment, highlighting clinical trial progress and financial details.

MBX Biosciences, a clinical-stage biopharmaceutical company, has filed an S-1 registration statement for an initial public offering to fund the development of its precision peptide therapies for endocrine and metabolic disorders.